TY  - JOUR
AU  - Sánchez Luna, Manuel Ramón
AU  - Burgos Pol, R.
AU  - Oyagüez, I.
AU  - Figueras Aloy, J.
AU  - Sánchez Solís, M.
AU  - Martinón Torres, F.
AU  - Carbonell Estrany, X.
PY  - 2017
DO  - 10.1186/s12879-017-2803-0
SN  - 1471-2334
UR  - https://hdl.handle.net/20.500.14352/99436
T2  - BMC Infectious Diseases
AB  - Background: This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory SyncytialVirus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain.Methods: A...
LA  - eng
M2  - 1471
PB  - BMC
KW  - Cost-effectiveness, Preterm infants, Palivizumab, RSV infection, Recurrent wheezing
TI  - Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
TY  - journal article
VL  - 17
ER  -